We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (ELM-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03888105
Recruitment Status : Recruiting
First Posted : March 25, 2019
Last Update Posted : January 5, 2023
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Tracking Information
First Submitted Date  ICMJE March 14, 2019
First Posted Date  ICMJE March 25, 2019
Last Update Posted Date January 5, 2023
Actual Study Start Date  ICMJE November 13, 2019
Estimated Primary Completion Date December 18, 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: June 29, 2021)
  • ORR (FL grade 1-3a/MZL) [ Time Frame: From first patient first dose until all patients have completed 52 weeks of study treatment or have withdrawn from the study ]
    For each of the 5 disease-specific cohorts according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by independent central review.
  • ORR (DLBCL/MCL/Other B-NHL) [ Time Frame: From first patient first dose until all patients have completed 36 weeks of study treatment or have withdrawn from the study ]
    For each of the 5 disease-specific cohorts according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by independent central review.
Original Primary Outcome Measures  ICMJE
 (submitted: March 20, 2019)
ORR [ Time Frame: From first dose until 194 weeks following the first dose ]
As measured by the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and according to independent central review, in patients with FL that has relapsed or is refractory to at least 2 prior lines of systemic therapy, including an anti-CD20 antibody and an alkylating agent.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 4, 2022)
  • ORR (FL/MZL) [ Time Frame: First patient first dose until all patients have completed 52 weeks of study treatment or have withdrawn from the study. ]
    According to the Lugano Classification, as assessed by local investigator evaluation
  • ORR (DLBCL/MCL/Other B-NHL) [ Time Frame: First patient first dose until all patients have completed 36 weeks of study treatment or have withdrawn from the study. ]
    According to the Lugano Classification, as assessed by local investigator evaluation
  • CR rate (FL grade 1-3a/MZL) [ Time Frame: First patient first dose until all patients have completed 52 weeks of study treatment or have withdrawn from the study. ]
    According to the Lugano Classification and as assessed by local investigator evaluation and independent central review
  • CR rate (DLBCL/MCL/Other B-NHL) [ Time Frame: First patient first dose until all patients have completed 36 weeks of study treatment or have withdrawn from the study. ]
    According to the Lugano Classification and as assessed by local investigator evaluation and independent central review
  • PFS [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    According to the Lugano Classification and as assessed by independent central review and local investigator evaluation
  • OS [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
  • DOR [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    According to the Lugano Classification and as assessed by independent central review and local investigator evaluation
  • DCR (FL grade 1-3a/MZL) [ Time Frame: First patient first dose until all patients have completed 52 weeks of study treatment or have withdrawn from the study. ]
    According to the Lugano Classification and as assessed by independent central review and local investigator evaluation
  • DCR (DLBCL/MCL/Other B-NHL) [ Time Frame: First patient first dose until all patients have completed 36 weeks of study treatment or have withdrawn from the study. ]
    According to the Lugano Classification and as assessed by independent central review and local investigator evaluation
  • Incidence and severity of treatment emergent adverse events (TEAEs) [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
  • Pharmacokinetics: Concentration of odronextamab [ Time Frame: 12 weeks following end of treatment ]
    End of infusion [EOI]; Concentration at a specified time t [Ct])
  • Incidence of anti-drug antibodies (ADA) to odronextamab over time [ Time Frame: 12 weeks following end of treatment ]
  • Titer of anti-drug antibodies to odronextamab over time [ Time Frame: 12 weeks following end of treatment ]
  • Incidence of neutralizing antibodies (Nab) to odronextamab over time [ Time Frame: 12 weeks following end of treatment ]
  • Changes in scores of patient-reported outcomes as measured by EORTC QLQ-C30 [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    EORTC QLQ-C30 is a self-reported, 30-item generic questionnaire developed to assess 15 domains: global health status scale, five functional scales (physical, role, emotional, cognitive, and social functioning) and nine symptom scales (fatigue, nausea, vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties).
  • Changes in scores of patient-reported outcomes as measured by FACT-Lym [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    Composed of the FACT-G plus the 15-item Lymphoma Subscale (LymS).
  • Changes in scores of patient-reported outcomes as measured by EQ-5D-3L [ Time Frame: First patient first dose to disease progression or death due to any cause, whichever comes first, approximately 194 weeks following the first dose ]
    The EQ-5D-3L is a standardized instrument for use as a measure of health outcome. It is a health questionnaire that consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.
Original Secondary Outcome Measures  ICMJE
 (submitted: March 20, 2019)
  • ORR [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by local investigator evaluation
  • CR rate [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by independent central review
  • CR rate [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by local investigator evaluation
  • PFS [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by independent central review
  • PFS [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by local investigator evaluation
  • OS [ Time Frame: From first dose until 194 weeks following the first dose ]
  • DOR [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by independent central review
  • DOR [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by local investigator evaluation
  • DCR [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by independent central review
  • DCR [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by local investigator evaluation
  • DDC [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by independent central review
  • DDC [ Time Frame: From first dose until 194 weeks following the first dose ]
    According to the Lugano Classification, as assessed by local investigator evaluation
  • Incidence and severity of treatment emergent adverse events (TEAEs) [ Time Frame: From first dose until 194 weeks following the first dose ]
  • Changes in scores of patient-reported outcomes as measured by EORTC QLQ-C30 [ Time Frame: From first dose until 194 weeks following the first dose ]
    EORTC QLQ-C30 is a self-reported, 30-item generic questionnaire developed to assess 15 domains: global health status scale, five functional scales (physical, role, emotional, cognitive, and social functioning) and nine symptom scales (fatigue, nausea, vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties).
  • Changes in scores of patient-reported outcomes as measured by EQ-5D-3L [ Time Frame: From first dose until 194 weeks following the first dose ]
    The EQ-5D-3L is a standardized instrument for use as a measure of health outcome. It is a health questionnaire that consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Official Title  ICMJE An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Brief Summary

Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by independent central review in each of the following B-cell non-Hodgkin lymphoma (B-NHL) subgroups:

  • In patients with follicular lymphoma (FL) grade 1-3a *1,2
  • In patients with diffuse large B-cell lymphoma (DLBCL) *1,2
  • In patients with mantle cell lymphoma (MCL) that has relapsed after or is refractory to a BTK inhibitor. This cohort will also include patients who have relapsed or have disease refractory to prior systemic therapy, or patients who have demonstrated intolerance to BTK inhibitor therapy, and who have progressed after other systemic therapy.
  • In patients with marginal zone lymphoma (MZL) *1
  • In patients with other B-NHL subtypes *1

Secondary objectives are:

  • To assess the anti-tumor activity of single agent odronextamab in each of 5 disease-specific cohorts, as measured by:
  • ORR according to the Lugano Classification and as assessed by local investigator evaluation
  • Complete response (CR) rate according to the Lugano Classification and as assessed local by local investigator evaluation and independent central review
  • Progression-free survival (PFS)*3
  • Overall survival (OS)
  • Duration of response (DOR)*3
  • Disease control rate (DCR)*3
  • To evaluate the safety and tolerability of odronextamab
  • To assess the pharmacokinetics (PK) of odronextamab
  • To assess the immunogenicity of odronextamab
  • To assess the effect of odronextamab on patient reported outcomes, including health-related quality of life (HRQL), as measured by the validated instruments European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym), and EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L)

    • 1 that has relapsed after or is refractory to at least 2 prior lines of systemic therapy
    • 2 including an anti-CD20 antibody and an alkylating agent
    • 3 according to Lugano Classification and as assessed by independent central review and local investigator evaluation
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
5 cohorts The first 68 patients in the DLBCL cohort will be randomized; the remaining patients will not be randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE B-cell Non-Hodgkin Lymphoma (NHL)
Intervention  ICMJE Drug: Odronextamab
Administered by intravenous (IV) infusion
Other Name: REGN1979
Study Arms  ICMJE
  • Experimental: FL
    Follicular lymphoma grade 1-3a cohort
    Intervention: Drug: Odronextamab
  • Experimental: DLBCL
    Diffuse large B-cell lymphoma cohort
    Intervention: Drug: Odronextamab
  • Experimental: MCL
    Mantle Cell Lymphoma cohort
    Intervention: Drug: Odronextamab
  • Experimental: MZL
    Marginal Zone Lymphoma cohort
    Intervention: Drug: Odronextamab
  • Experimental: Other B-NHL
    Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia [WM]); Patients with a current diagnosis of mixed histology of B-NHL with an aggressive component (such as concurrent FL and DLBCL) will be allowed
    Intervention: Drug: Odronextamab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 29, 2021)
512
Original Estimated Enrollment  ICMJE
 (submitted: March 20, 2019)
112
Estimated Study Completion Date  ICMJE February 4, 2028
Estimated Primary Completion Date December 18, 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • For the FL grade 1-3a cohort only: Central histopathologic confirmation of the FL Grade 1 to 3a diagnosis must be obtained before study enrollment. Patients with FL grade 3b are ineligible for this cohort but may be included in the "other B-NHL" cohort. Follicular lymphoma subtyping is based on the World Health Organization (WHO) classification (Swerdlow, 2017).
  • Disease-specific cohorts that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol
  • DLBCL cohort: Patients with DLBCL that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol
  • MCL after BTK inhibitor therapy cohort: New enrollment is paused until further notice
  • MZL cohort: New enrollment is paused until further notice
  • Other B-NHL cohort: Patients with B-NHL other than FL grade 1-3a, DLBCL, MCL, or MZL that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol. New enrollment stopped for patients with Burkitt lymphoma and Burkitt-like lymphoma.
  • Patients should in the judgment of the investigator require systemic therapy for lymphoma at the time of study enrollment
  • Measurable disease on cross sectional imaging as defined in the protocol documented by diagnostic imaging (computed tomography (CT), or magnetic resonance imaging (MRI)
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Adequate bone marrow, hepatic, and renal function as defined in the protocol

Key Exclusion Criteria:

  • Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS Non-Hodgkin Lymphoma (NHL) (suspected CNS lymphoma should be evaluated by lumbar puncture, as appropriate, in addition to the mandatory head CT or MRI).
  • Treatment with any systemic anti-lymphoma therapy within 5 half-lives or within 28 days prior to first administration of study drug, whichever is shorter.
  • History of allogeneic stem cell transplantation
  • Prior treatment with any chimeric antigen receptor T-cell (CAR-T) therapy
  • Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or anti-inflammatory equivalent within 72 hours of start of study drug
  • History of neurodegenerative condition or CNS movement disorder. Patients with a history of seizure within 12 months prior to study enrollment are excluded
  • Another malignancy except B-NHL in the past 5 years, with the exception of non-melanoma skin cancer that has undergone potentially curative therapy or in situ cervical carcinoma, or any other tumor that has been deemed to be effectively treated with definitive local control and with curative intent.
  • Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; cytomegalovirus (CMV) infection as noted by detectable levels on a blood polymerase chain reaction (PCR) assay as defined in the protocol or other uncontrolled infections
  • Known hypersensitivity to both allopurinol and rasburicase
  • Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Clinical Trials Administrator 844-734-6643 clinicaltrials@regeneron.com
Listed Location Countries  ICMJE Australia,   Canada,   China,   France,   Germany,   Italy,   Japan,   Korea, Republic of,   Poland,   Singapore,   Spain,   Taiwan,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03888105
Other Study ID Numbers  ICMJE R1979-ONC-1625
2017-002139-41 ( EudraCT Number )
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Informed Consent Form (ICF)
Supporting Materials: Clinical Study Report (CSR)
Supporting Materials: Analytic Code
Time Frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
Access Criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
URL: https://vivli.org/
Current Responsible Party Regeneron Pharmaceuticals
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Regeneron Pharmaceuticals
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Trial Management Regeneron Pharmaceuticals
PRS Account Regeneron Pharmaceuticals
Verification Date September 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP